NEWARK, Calif.--(BUSINESS WIRE)--May 14, 2019--
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company
developing next-generation neuromodulators for use in treating aesthetic
and therapeutic conditions, today announced that the company will
participate in the RBC Capital Markets 2019 Healthcare Conference in New
President and Chief Executive Officer, Dan Browne, is scheduled to make
a fireside presentation on Tuesday, May 21 at 9:30 a.m. ET.
Interested parties can access the live audio webcast for this conference
from the Investor Relations section of the company's website at www.revance.com.
The webcast replay will be available after the conclusion of the live
presentation for approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company focused on developing
transformative neuromodulators to address a broad spectrum of aesthetic
and therapeutic conditions. Revance’s lead product candidate,
DaxibotulinumtoxinA for Injection (DAXI), utilizes a unique proprietary
peptide excipient technology combined with highly purified botulinum
toxin type A to produce a novel, long-acting neuromodulator set to enter
a $4.5 billion global market. In aesthetics, Revance successfully
completed its Phase 3 program for DAXI in glabellar (frown) lines and is
currently pursuing U.S. regulatory approval in 2020, while also running
two separate Phase 2 studies in forehead lines and lateral canthal lines
(crow’s feet). In therapeutics, DAXI is being studied in three
indications, including a Phase 3 trial in cervical dystonia, a Phase 2
trial in adult upper limb spasticity, and a Phase 2 trial in plantar
fasciitis, with plans to also study migraine. Beyond DAXI, Revance also
has begun development of a biosimilar to BOTOX®, which would compete in
the existing short-acting neuromodulator marketplace. More information
on Revance may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
BOTOX® is a registered trademark of
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005850/en/
Source: Revance Therapeutics, Inc.
Revance Therapeutics, Inc.:
Laurence Watts, 619-916-7620
Jenifer Slaw, 347-971-0906
Nadine Tosk, 504-453-8344